中药复方治疗多重或广泛耐药细菌性肺炎:Meta分析与试验序贯分析及关联规则挖掘核心药对
Meta分析显示联合治疗在提高有效率、微生物清除率、降低炎症指标及缩短住院时间方面优于单用抗生素,试验序贯分析证实有效率和微生物清除结果稳健。关联规则分析识别出黄芩、浙贝母、金银花、甘草为核心中药组合。
要点
- 中药复方联合抗生素较单用抗生素提高耐药细菌性肺炎治疗有效率和微生物清除率。
- 联合治疗可降低白细胞计数、降钙素原、C反应蛋白、CPIS及APACHE-II评分,缩短住院时间。
- 黄芩、浙贝母、金银花、甘草被识别为核心中药组合,但需大规模临床研究验证。
核心结论
- 与单用抗生素相比,中药复方联合抗生素在提高有效率、微生物清除率、改善炎症反应、CPIS和APACHE-II评分及缩短住院时间方面更优。
- 关联规则分析识别出黄芩、浙贝母、金银花、甘草四种核心中药,为治疗耐药细菌性肺炎的潜在候选药物。
研究设计与样本
- 使用Stata 16软件进行Meta分析,TSA 0.9.5.10 beta软件进行试验序贯分析,通过Meta回归和亚组分析探索异质性来源。
主要发现
- 中药复方联合抗生素提高有效率(RR=1.24;95%CI:1.19-1.28;p<0.0001)和微生物清除率(RR=1.41;95%CI:1.27-1.57;p<0.0001)。
- 联合治疗降低白细胞计数(MD=-2.09;95%CI:-2.65至-1.53;p<0.0001)、降钙素原(MD=-0.49;95%CI:-0.59至-0.40;p<0.0001)、C反应蛋白(MD=-11.80;95%CI:-15.22至-8.39;p<0.0001)。
- 联合治疗降低CPIS(MD=-1.97;95%CI:-2.68至-1.26;p<0.0001)和APACHE-II评分(MD=-4.08;95%CI:-5.16至-3.00;p<0.0001),缩短住院时间(MD=-4.79;95%CI:-6.18至-3.40;p<0.0001),减少不良事件数量。
- 试验序贯分析表明有效率和微生物清除率结果稳健。
关键数值与推荐
- 有效率RR=1.24(95%CI:1.19-1.28;p<0.0001),微生物清除率RR=1.41(95%CI:1.27-1.57;p<0.0001)。
- 白细胞计数MD=-2.09(95%CI:-2.65至-1.53;p<0.0001),降钙素原MD=-0.49(95%CI:-0.59至-0.40;p<0.0001),C反应蛋白MD=-11.80(95%CI:-15.22至-8.39;p<0.0001)。
- CPIS MD=-1.97(95%CI:-2.68至-1.26;p<0.0001),APACHE-II评分MD=-4.08(95%CI:-5.16至-3.00;p<0.0001),住院时间MD=-4.79(95%CI:-6.18至-3.40;p<0.0001)。
临床怎么用
- 对于多重或广泛耐药细菌性肺炎,可考虑在抗生素治疗基础上联合中药复方以改善疗效和炎症指标。
- 核心中药组合黄芩、浙贝母、金银花、甘草可作为处方参考,但需结合辨证论治。
- 联合治疗可能减少不良事件并缩短住院时间,但需监测患者反应。
局限性
- 仍需大规模临床研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: Antibiotic-resistant bacterial pneumonia poses a significant therapeutic challenge. In China, Chinese herbal compound (CHC) is commonly used to treat bacterial pneumonia. We aimed to evaluate the efficacy and safety of CHC and identify core herb combinations for the treatment of multidrug-resistant or extensively drug-resistant bacterial pneumonia. Methods: Stata 16 and TSA 0.9.5.10 beta software were used for meta-analysis and trial sequential analysis (TSA), respectively. Exploring the sources of heterogeneity through meta-regression and subgroup analysis. Results: Thirty-eight studies involving 2890 patients were included in the analyses. Meta-analysis indicated that CHC combined with antibiotics improved the response rate (RR = 1.24; 95% CI: 1.19-1.28; p < 0.0001) and microbiological eradication (RR = 1.41; 95% CI: 1.27-1.57; p < 0.0001), lowered the white blood cell count (MD = -2.09; 95% CI: -2.65 to -1.53; p < 0.0001), procalcitonin levels (MD = -0.49; 95% CI: -0.59 to -0.40; p < 0.0001), C-reactive protein levels (MD = -11.80; 95% CI: -15.22 to -8.39; p < 0.0001), Clinical Pulmonary Infection Scores (CPIS) (MD = -1.97; 95% CI: -2.68 to -1.26; p < 0.0001), and Acute Physiology and Chronic Health Evaluation (APACHE)-II score (MD = -4.08; 95% CI: -5.16 to -3.00; p < 0.0001), shortened the length of hospitalization (MD = -4.79; 95% CI: -6.18 to -3.40; p < 0.0001), and reduced the number of adverse events. TSA indicated that the response rate and microbiological eradication results were robust. Moreover, Scutellaria baicalensis Georgi, Fritillaria thunbergii Miq, Lonicera japonica Thunb, and Glycyrrhiza uralensis Fisch were identified as core CHC prescription herbs. Conclusion: Compared with antibiotic treatment, CHC + antibiotic treatment was superior in improving response rate, microbiological eradication, inflammatory response, CPIS, and APACHE-II score and shortening the length of hospitalization. Association rule analysis identified four core herbs as promising candidates for treating antibiotic-resistant bacterial pneumonia. However, large-scale clinical studies are still required. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023410587.
引用
- Zhao S, Geng Y, Shi J, et al. Chinese herbal compound for multidrug-resistant or extensively drug-resistant bacterial pneumonia: a meta-analysis and trial sequential analysis with association rule mining to identify core herb combinations. Front Pharmacol. 2023. PMID: 38174222. doi:10.3389/fphar.2023.1282538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。